Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication January 13, 2022
- Revision received April 7, 2022
- Published online June 1, 2022.
Copyright & Usage
© 2022 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- 1Tulane University School of Medicine, Tulane Cancer Center, New Orleans, Louisiana; and
- 2University of Duisburg–Essen and German Cancer Consortium, University Hospital Essen, Essen, Germany
- Learning Objectives: On successful completion of this activity, participants should be able to describe (1) selection criteria employed in the VISION trial; (2) the VISION trial in the context of other therapies for advanced prostate cancer; and (3) an overview of newer phase III protocols using radiopharmaceuticals in the treatment of advanced prostate cancer.Financial Disclosure: Dr. Sartor is a consultant/advisor for Advanced Accelerator Applications (AAA), Amgen, Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Curium, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen, JNJ, Myovant, Myriad, Noria Therapeutics, Inc., Novartis, Noxopharm, Nucligen, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, and Theragnostics; has investment interest in Clarity, Lantheus, Noria, Ratio, Nucligen, and Telix; and is an investigator for Advanced Accelerator Applications, Amgen, AstraZeneca, Bayer, Constellation, Endocyte, Invitae, Janssen, Lantheus, Merck, POINT, Biopharma, Progenics, and Tenebio. Dr. Herrmann is a consultant to AAA, AstraZeneca, Bayer Healthcare, JNJ, Novartis, Curium, and Amgen; receives personal fees from Bayer, Sofie Biosciences, SIRTEX, Adacap, Curium, Endocyte, BTG, IPSEN, Siemens Healthineers, GE Healthcare, Amgen, Novartis, ymabs, Aktis Oncology, Theragnostics, Pharma15, Debiopharm, AstraZeneca, and Janssen; received a grant from BTG; received nonfinancial support from ABX; and received other support from Sofie Biosciences. The authors of this article have indicated no other relevant relationships that could be perceived as a real or apparent conflict of interest.CME Credit: SNMMI is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNMMI designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only credit commensurate with the extent of their participation in the activity. For CE credit, SAM, and other credit types, participants can access this activity through the SNMMI website (http://www.snmmilearningcenter.org) through June 2025.
- For correspondence or reprints, contact Oliver Sartor (osartor{at}tulane.edu).
Statistics from Altmetric.com
Article usage
In this issue
Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations
Jump to section
Related Articles
Cited By...
- No citing articles found.